Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-436444

Options or other derivatives

  • Chief Financial Officer acquired 27,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Silver Andrew Jacob · Chief Financial Officer

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-10-26 Grant or award : show line 1 in the form Stock Option (Right to Buy) +18,000 18,000 D
2026-10-26 Grant or award : show line 2 in the form Restricted Stock Units +9,000 9,000 D
Loading xslF345X06/ownership.xml…